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Conclusions: This multicenter registry demonstrates a satisfactory and sustained 5-year
clinical safety and efficacy profiles, as evidenced by low rates of major adverse cardiac
events and definite stent thrombosis, for the Excel biodegradable polymer-based
sirolimus-eluting stent when treated by 6 months dual antiplatelet therapy for an
unselected Asian patient population.
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Background: Polymer-free sirolimus-and probucol-eluting stents (Real Dual DES) is as
effective as first-generation DES in treating coronary artery stenosis. It is unknown
whether sirolimus-eluting stents containing biodegradable polymer (Excel) would be
superior to real Dual DES. The present study aimed to investigate the difference in target
vessel revascularization (TVR) at 12 months in patients with coronary artery disease
treated by the implantation of Dual DES or Excel stents.
Methods: 346 patients with de novo coronary artery disease were recruited from 6
centers in China and randomly assigned to either the Dual DES or the Excel group. The
primary endpoint was the occurrence of TVR at 12 months. The secondary endpoint was
angiographic in-stent restenosis (ISR) and late lumen loss at 13 months. Stent thrombosis
(ST) served as the safety endpoint. Dual anti-platelet therapy (DAPT) was prescribed for
6-month.
Results: Clinical follow-up at 12 months and repeat angiography at 13 months were
available in 100% and90% of patients, respectively. The ISR and in-stent late loss were
significantly different between the Excel (3.1%, 0.090.11 mm) and the Dual DES
(19.5%,0.360.32 mm, p0.001, p0.001, respectively) groups. The TVR(3.5%) in the
Excel group was significantly less than in the Dual DES group (13.9%, p0.001). The ST
rate beyond 12 months in the Dual DES group was 0%, and this was 1.2% in the Excel
group (p0.499).
Conclusions: The Excel stent was statistically superior to the Dual DES in terms of
restenosis, late loss and TVR for long lesions.
Clinical outcomes
Dual DES
(n173)
Excel
(n173) p
Intra-procedure, n (%) 0 0 NS
Death 0 0 NS
Myocardial infarction 0 0 NS
Target lesion revascularization 0 0 NS
CABG 0 0 NS
Target vessel revascularization 0 0 NS
Composite MACE 0 0 NS
Stent thrombosis 0 0 NS
In-hospital, n (%)
Death 0 1 (0.6) 0.500
Cardiac 0 1 (0.6) 0.500
Non-cardiac 0 0 NS
Myocardial infarction 2 (1.2) 6 (3.5) 0.283
ST-elevation MI 0 4 (2.3) 0.123
Non-ST-elevation MI 2 (1.2) 2 (1.2) 1.000
Target lesion revascularization 0 0 NS
CABG 0 1 (0.6) 0.500
Target vessel revascularization 0 1 (0.6) 0.500
Composite MACE 4 (2.3) 6 (3.5) 0.750
Stent thrombosis 0 1 (0.6) 0.500
Procedural success 167 (96.5) 166 (96.0) 1.000
At 12-month follow-up
Death 0 1 (0.6) 0.499
Cardiac 0 1 (0.6) 0.499
Non-cardiac 0 0 NS
Myocardial infarction 2 (1.2) 6 (3.5) 0.283
ST-elevation MI 0 4 (2.3) 0.123
Non-ST-elevation MI 2 (1.2) 2 (1.2) 1.000
Target lesion revascularization 16 (9.2) 3 (1.7) 0.003
CABG 0 1 (0.6) 0.500
Target vessel revascularization 24 (13.9) 6 (3.5) 0.001
Composite MACE 25 (14.5) 12 (6.9) 0.036
Stent thrombosis 0 3 (1.8) 0.101
Definite 0 2 (1.2) 0.499
Probable 0 0 NS
possible 0 1 (0.6) 0.500
CABG,coronary artery bypass graft; MACE, major adverse coronary event; MI,
myocardial infarction
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Background: Patients with diabetes mellitus (DM) undergoing percutaneous cardiovas-
cular intervention (PCI) represent a challenging population with higher risk of adverse
events compared to non-diabetic patients. We investigated the impact of DM on long-term
clinical outcomes of biolimus-eluting stents (BES) with biodegradable polymer versus
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